(1S,5R)-1-phenyl-3-oxa-bicyclo[3.1.0]hexan-2-one is supplied as a single-enantiomer pharmaceutical-grade active pharmaceutical ingredient for direct formulation into tablet, capsule, granule, oral solution, and injectable dosage forms. The compound contains a fused cyclopropane-oxalactone system in which the 1S and 5R stereocentres are fixed by the bicyclic scaffold; this stereochemical arrangement differentiates it from the corresponding 1R,5S enantiomer and from racemic mixtures that may exhibit different crystal packing, hygroscopicity, and pharmacological activity. The API is released with a certificate of analysis covering identity by infrared spectroscopy and chiral high-performance liquid chromatography, assay by HPLC, related substances, residual solvents, elemental impurities, and, for injectable use, bacterial endotoxins. Depending on the downstream terminal sterilisation or aseptic processing strategy, the material can be supplied with reduced bioburden and controlled particulate burden. In solid oral processing, the material is normally jet-milled or pin-milled under nitrogen to a controlled particle size range; sieve classification is used to limit coarse agglomerates that could affect content uniformity in low-dose tablet or capsule blends. Because the fused cyclopropane-lactone is strained, mechanical energy during blending and lubrication should be limited, and exposure to humid air should be controlled to reduce hydrolytic ring opening.

How Are Oral and Injectable Release Specifications Distinguished?

Release specifications for oral and injectable grades differ primarily in the risk controls applied to water content, bioburden, endotoxin, particulate matter, and total related substances. The matrix below summarises a control strategy aligned with ICH Q3A, Q3C, and Q3D, and relevant USP general chapters. Because published data for this specific configuration is limited, acceptance limits shown represent compendial or risk-based default thresholds rather than batch-derived product-specific values; the manufacturer’s certificate of analysis should be used as the authoritative release document.

Solid-state control for this API centres on polymorph and particle-size stability. X-ray powder diffraction patterns should be compared against the designated reference pattern for the 1S,5R form; the absence of characteristic peaks from the racemate or the 1R,5S enantiomer is used as confirmation of crystallographic phase purity. Differential scanning calorimetry is used to monitor whether the fused oxa-bicycle undergoes ring-opening or recrystallisation during wet granulation. Published data for this specific configuration is limited, so forced degradation studies performed at 40 °C/75% RH and 60 °C dry conditions are required to define the allowable granulating fluid exposure. Particle size distributions are measured by laser diffraction according to USP<786>; for direct-compression tablet grades, control of the D90 below 150 µm is commonly used to support content uniformity, while the D10 is maintained above 10 µm to reduce segregation. Powder flow is evaluated by the angle of repose and Carr index; if the API alone presents a flow function coefficient below 4 on an annular shear cell, glidant addition or roller compaction is normally required. In capsule filling, dosator or tamping-pin machines can densify low-bulk-density milled material; fill weight variability should be assessed across at least 300 capsules as part of process qualification.

Chiral Purity and Enantiomeric Distinction from Racemic and Diastereomeric Lactones

Chiral purity is a critical quality attribute because the bicycle contains fixed stereocentres whose inversion would require covalent bond cleavage in the cyclopropane ring. However, epimerisation at the bridgehead can occur under strongly basic or acidic conditions, and chiral HPLC is used to quantify the unwanted enantiomer and diastereomeric impurities. The method is usually a normal-phase system with a polysaccharide-based chiral stationary phase; resolution between the 1S,5R and 1R,5S forms should be not less than 1.5. For oral grades, an enantiomeric excess of ≥ 99.0% is typical; for injectable grades, the tighter ≥ 99.5% value is often applied because the injectable route may require a reduced burden of pharmacologically or toxicologically undefined enantiomers. Differences from racemic or diastereomeric products arise in XRPD, melting point, specific rotation, and dissolution behaviour. A racemate may form a conglomerate or racemic compound with different lattice energy, resulting in altered solubility and different milling behaviour; the single enantiomer is selected when the pharmacological target is stereospecific. The 1S,5R form is differentiated from other bicyclic lactones such as 3-azabicyclo[3.1.0]hexan-2-ones by the presence of the oxygen at the 3-position; this substitution modifies hydrogen-bonding capability, log P, and hydrolytic stability.

Residual Solvent and Elemental Impurity Control Follows ICH Q3C and Q3D Risk-Based Limits

Residual solvents in this API are controlled through the synthetic route and drying cycle. Because the compound is a small-molecule API, the most commonly encountered residual solvents are alkanes, esters, or chlorinated solvents depending on the chiral resolution route. The release specification follows ICH Q3C Class 1 and Class 2 limits and requires Class 3 solvents to be below 0.5% w/w total. If the manufacturing route introduces a Class 1 solvent such as benzene or carbon tetrachloride, the limit applies on a per-solvent basis and cannot be offset by Class 2 or 3 contributions. Elemental impurities are assessed under ICH Q3D using Option 1: the maximum daily intake of the finished dosage form is used to set permitted concentrations for the 24 elements; for injectables, the same PDE-based approach applies, but the contribution of the container-closure system and water-for-injection is added to the risk assessment. Typical API-level limits for Class 1 and Class 2A catalysts such as palladium or nickel are aligned with ICH Q3D oral and parenteral PDE values, and the API manufacturer provides a risk assessment rather than only a declaration covering each element intentionally introduced in the synthesis.

The injectable route introduces additional controls beyond chemical purity. The API is manufactured under a low-bioburden environment, and the bacterial endotoxin limit is established from the maximum dose per kilogram administered by the intended route; for many parenteral formulations, a limit of ≤ 0.25 EU/mg is applied when the maximum daily dose is 100 mg or less, but this is dose-dependent and must be recalculated. Sterility is not necessarily a release attribute for the API; the finished medicinal product is terminally sterilised or aseptically filtered. If the API is pre-sterilised by gamma irradiation or ethylene oxide, it must be demonstrated that the fused cyclopropane-lactone ring is stable and that no new related substances are generated above 0.10%. For injectable solution manufacturing, the API is dissolved in water-for-injection, and the solution is passed through a 0.22 µm sterilising filter; filter compatibility and adsorption losses should be evaluated because this compound may bind to hydrophobic filter membranes. Particulate matter after reconstitution is controlled under USP<788> small-volume injectable limits: ≤ 6000 particles per container at ≥ 10 µm and ≤ 600 particles per container at ≥ 25 µm. Stability of injectable solutions should include pH, osmolality, visible and subvisible particles, and chiral purity at accelerated and long-term storage conditions.

When Formulated Into Tablets and Capsules, Processing Conditions Must Limit Hydrolytic Ring Opening

The strained 3-oxa-bicyclo[3.1.0]hexan-2-one ring is susceptible to hydrolysis at the lactone linkage; therefore, aqueous granulation and high-humidity storage should be considered in the formulation strategy. Dry granulation by roller compaction is preferred when the API is moisture-sensitive; if wet granulation is unavoidable, the granulating fluid should be limited to 5–15% w/w of the dry powder mass, and the wet mass should be dried to a final water content below 0.5% w/w. In direct compression, magnesium stearate is typically limited to 0.5–1.0% w/w and blending time is capped to avoid overlubrication that can slow dissolution. For low-dose tablets, a pre-blend step with an intragranular portion is used to improve content uniformity. Tablet hardness values are set by the disintegration and dissolution profile; for an immediate-release oral tablet, USP<711> dissolution testing in 0.1 N HCl or pH 6.8 phosphate buffer is used to confirm release. Capsule formulations may require slugging or roller compaction if the milled API has a bulk density below 0.35 g/mL. Capsules should be stored in HDPE containers with desiccant if the API degrades under open-dish 40 °C/75% RH conditions.

Storage recommendations are based on forced degradation data; when data are not yet available for this configuration, the API is stored under refrigerated conditions at 2–8 °C in sealed, light-protected containers. Retest intervals are assigned according to ICH Q1A; the manufacturer’s stability batches should cover long-term 25 °C/60% RH and accelerated 40 °C/75% RH conditions. The difference from non-pharma-grade material is the absence of compendial documentation and controlled chiral purity; non-certified material is not suitable for use under FDA 21 CFR Part 210/211 because the vendor may not provide cleaning validation, process change control, or residual solvent and elemental impurity data.